Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Express Scripts Adds Diabetes, Inflammatory Drugs to Value Pricing Plan

By Ryan Bushey | September 12, 2016

The issue of high drug prices has raised a number of concerns with insurers and employers searching for strategies to provide patients with the most cost-effective payment plans.

Express Scripts, the country’s largest pharmacy benefits manager, is testing out a value-based pricing plan for inflammatory and diabetes drugs.

The organization will partner with another company “to help educate patients and keep them on track taking their meds but then refund up to $6,000 if a patient discontinues any preferred anti-inflammatory medication within the first 90 days,” reported FiercePharma.

Inflammatory disease treatments like Humira were lumped together in coverage plans despite targeting different ailments so Express Scripts’s new plan would allow it to treat these conditions differently based on each approved drug.

Diabetes drugs were added to this value-based program last week too. This particular initiative, though, focuses on guaranteeing per-patient spending caps for clients in an effort to drive down costs and help increase adherence. Patients taking part in participating plans will be able to receive 90-day supplies of their diabetes medication while being able to access clinical counseling from pharmacists participating in Express Scripts network.

The intent of these programs is to hopefully force drug companies to lower their prices giving institutions like pharmacy benefits managers more flexibility in managing drugs for these expensive diseases, wrote The New York Times.

Other pharmacy benefits managers are trying different tactics. CVS changed its coverage plan for 2017 by favoring biosimilars, drugs that could save the healthcare system over $110 billion in four years.

Express Scripts inflammatory drug program goes into effect January 2017 while the diabetes one will activate in March of that year.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50